BRUIN CLL-322 is the first Phase 3 study to demonstrate superiority over a venetoclax-containing control arm in CLL, and, with the majority of patients previously treated with a covalent BTK inhibitor, reflects current practice patterns These data will be highlighted in a late-breaking oral presentation at the 2026 European Hematology Association (EHA) Annual Meeting June 14, 2026 -- Eli Lilly and Company (NYSE: LLY) today announced results from the Phase 3 BRUIN CLL-322 clinical trial of Jayp

June 13, 2026 -- Kos Biotechnology Partners ("Kos"), a global life sciences investment firm bridging the US biopharma ecosystem with Europe, today announced the third closing of its inaugural global life sciences fund, bringing total capital commitments to $123M (€106M). Following its initial launch in December 2025, the fund has secured backing from a syndicate of prominent institutional investors—including lead investor Hellenic Development Bank of Investments (HDBI)—and global family offices.

-- Patients with PWS treated with setmelanotide therapy (N=17) achieved clinically meaningful BMI or BMI z-score reductions, reductions in fat mass with preservation of lean mass, and improvements in hyperphagia and anxiety measures -- -- Positive results reinforce rationale for Phase 3 development of MC4R agonism in PWS -- -- Company to hold conference call on Saturday, June 13, at 8 a.m. CT, 9 a.m. ET -- June 13, 2026 -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage

June 12, 2026 -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced the completion of its rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for tinlarebant. Tinlarebant is an investigational, once-daily oral therapy for the treatment of Stargardt disease t

June 12, 2026 -- Transcend Therapeutics today announced the completion of its acquisition by Otsuka America Inc., a subsidiary of Otsuka Pharmaceutical Co., Ltd. (Otsuka), marking a significant milestone in Transcend's mission to develop rapid-acting treatments for neuropsychiatric diseases, including post-traumatic stress disorder (PTSD). The acquisition was originally announced on March 27, 2026. With the completion of the transaction, Transcend is now a wholly owned subsidiary of Otsuka Amer

June 12, 2026 -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced top-line results from the Phase 3 LAGOON trial, conducted by PharmaMar, evaluating Zepzelca® (lurbinectedin) in patients with relapsed (second-line) metastatic small cell lung cancer (SCLC). The trial did not meet its primary endpoint of overall survival (OS) evaluating Zepzelca as monotherapy or in combination with irinotecan compared to investigators' choice of topotecan or irinotecan. No new safety signals were identifie

June 12, 2026 -- AbbVie (NYSE: ABBV) today announced new Phase 3 data on a fixed-duration venetoclax-based combination at the European Hematology Association (EHA) 2026 Congress taking place June 11-14 in Stockholm, Sweden. Final results from the Phase 3 CLL14 trial in previously untreated chronic lymphocytic leukemia (CLL), which was conducted in collaboration with the German CLL Study Group, will be featured in an oral presentation. "The nine-year results from the landmark Phase 3 CLL14 trial

June 12, 2026 -- On May 29, 2026, Pacific Time, Simcere Pharmaceutical Group Limited (2096.HK) entered into a research collaboration agreement with Stanford Medicine to jointly advance an exploratory study in the respiratory field, with the aim of developing innovative therapies for patients with idiopathic pulmonary fibrosis (IPF). According to the agreement, Simcere Pharmaceutical will fund the exploratory research of this first-in-class novel molecule. Upon successful completion, Simcere wil

The FDA has approved a combination of Merck & Co.'s Keytruda (pembrolizumab) with the company's HIF-2α inhibitor Welireg (belzutifan) as an adjuvant treatment for adults with clear cell renal cell carcinoma (ccRCC) at risk of recurrence after surgery. The approval also applied to Keytruda's subcutaneous formulation, Keytruda Qlex (pembrolizumab/berahyaluronidase alfa-pmph). The decision, which follows a priority review, is based on the Phase III LITESPARK-022 trial, which enrolled 1841 patients

June 11, 2026 -- Akeso, Inc. (9926.HK) today announced that the National Medical Products Administration (NMPA) of China has approved gumokimab (AK111), the company's internally-developed anti-IL-17 monoclonal antibody, for the treatment of adult patients with moderate-to-severe plaque psoriasis. The approval was supported by one pivotal Phase III clinical study (AK111-301) and three supportive studies. Study results demonstrate gumokimab's rapid and robust efficacy, durable complete skin clear